LB1410 not checked

L & L Bio Co., Ltd., Ningbo, China

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
3 active
3 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Solid Tumor (2 trials), Cervical Cancer, Lymphoma
Main trialPhase 2/3
“This is a multicenter, randomized, open-label Phase II/III clinical study, aiming to evaluate the efficacy and safety of LB1410 in combination with lenvatinib (whether in combination with LB4330)versus the chemotherapy regimen selected by the investigators for patients with advanced recurrent/metastatic cervical cancer.”In the company’s words, NCT07177716 on ClinicalTrials.gov

Other drugs for Solid Tumor

All 2440 drugs for Solid Tumor

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting Dec 2028 Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer
Phase 1/2Recruiting 30 Dec 2026 A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Phase 1Recruiting 30 Dec 2026 A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LB1410

Following is part of Solo: you see every change to LB1410 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in